Skip to main content

Table 1 Patient characteristics

From: Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

Pt #

Age

Race

ER or PR +

# prior lines tx

# met sites

Trastuzumab in prior regimen (days since)

Prior Lapatinib

# injections

PFS (d)

OS (d)

001

45

W

Y

4

2

Y (23)

N

4

53

615+

002

50

W

Y

3

3

Y (34)

P

6

82

484

003

48

W

N

3

4

Y (24)

C

6

85

596+

004

53

W

N

6

1

N

C

6

86

549+

005

63

W

Y

2

2

N

C

4

48

540+

006

60

W

N

5

4

Y (37)

C

6

86

531+

007

46

B

N

4

1

Y (33)

P

5

69

486+

008

65

W

N

8

3

Y (27)

C

3

41

456+

012

55

W

N

3

2

N

C

5

69

216

013

65

W

N

4

2

Y (27)

C

4

55

316+

014

56

W

N

3

2

Y (25)

C

12

188

310+

015

46

B

Y

3

4

Y (21)

N

4

69

274+

Median

54

  

3.5

2

  

5

69

 
  1. 1) Prior Lapatinib Use (N = no prior use, P = previous progression on lapatinib, but not on regimen immediately prior, C = continued use, patient was on lapatinib in immediately prior regimen and continued the medication onto trial). 2) OS (overall survival): "+" indicates that the patient was still alive at the last follow-up date